## For Research Use Only **Tanzisertib**



www.ptgcn.com

## Catalog Number: CM04920

产品信息

Catalog Number: CM04920

CAS号: 899805-25-5

 $C_{21}H_{23}F_3N_6O_2$ 

主要靶点: JNK

主要通路: MAPK信号通路

分子量: 448.44 溶解度:

DMSO:33 mg/mL (73.59 mM)

靶点活性

JNK2:7 nM|JNK1:61 nM|JNK3:6 nM

体外活性

Tanzisertib (CC-930) inhibits the formation of phospho-cJun in human PBMC stimulated by phorbol-12-myristate-13-acetate and phytohemeagglutinin (IC50=1  $\mu$  M)[1] and it blocks the JNK pathway that is activated by pro-fibrotic cytokines in systemic sclerosis[3]. Tanzisertib (CC-930) (1-2  $\mu$  M) substantially reduces hepatocyte apoptosis and necrosis, abrogates apoptosis and necrosis in FC-loaded WT hepatocytes[2].

体内活性

Tanzisertib (CC-930) (10 and 30 mg/kg, p.o.) inhibits the production of TNFa by 23% and 77% in the acute rat LPS-induced TNFa production PK-PD model[1]. Tanzisertib (CC-930) (150 mg/kg) prevents the development of fibrosis in different models. However, it can also induce the regression of pre-existing fibrosis[3].

描述

Tanzisertib (CC-930) is a potent inhibitor of JNK1/2/3 with IC50s of 61/7/6 nM, respectively, with potential antifibrotic

Powder: -20°C for 3 years | In solvent: -80°C for 2 years